Kintz Samuel 4
4 · Enliven Therapeutics, Inc. · Filed Sep 25, 2025
Insider Transaction Report
Form 4
Kintz Samuel
DirectorPRESIDENT AND CEO
Transactions
- Sale
Common Stock
2025-09-23$20.03/sh−2,800$56,084→ 919,092 total(indirect: See footnote)
Footnotes (2)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
- [F2]The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.